Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
Crossref DOI link: https://doi.org/10.1007/s11523-020-00761-7
Published Online: 2020-10-20
Published Print: 2020-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lüftner, Diana
Lyman, Gary H.
Gonçalves, João
Pivot, Xavier
Seo, Minji
Text and Data Mining valid from 2020-10-20
Version of Record valid from 2020-10-20
Article History
First Online: 20 October 2020
Free to read: This content has been made available to all.